Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease

Kaya, Eda; undefined, Enas sawah; Daneshgar, Fatemeh; Hikal, Yousra; Özel, Furkan; Lüleci, Nimet Emel; Eris, Tansu; Hassan, Moomen; Teker, Ayse Gulsen; Yilmaz, Yusuf

doi:10.14744/hf.2022.2022.0042

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease

Tansu Eris, (Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Moomen HASSAN, (Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Yousra Hikal, (Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Enas SAWAH, (Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Fatemeh DANESHGAR, (Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Ayşe Gülsen TEKER, (Halk Sağlığı Anabilim Dalı, Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Furkan ÖZEL, (Halk Sağlığı Anabilim Dalı, Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Nimet Emel LÜLECİ, (Halk Sağlığı Anabilim Dalı, Marmara Üniversitesi Tıp Fakültesi, İstanbul, Türkiye)

Eda KAYA, (Department of Internal Medicine, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany)

Yusuf YILMAZ (Karaciğer Araştırma Birimi, Gastroenteroloji Enstitüsü, Marmara Üniversitesi, İstanbul, Türkiye)

Hepatology forum

6 0

Yıl: 2023 Cilt: 4 Sayı: 1 Sayfa Aralığı: 7 - 13 Metin Dili: İngilizce DOI: 10.14744/hf.2022.2022.0042 İndeks Tarihi: 04-06-2023

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease

Öz:

Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi- broScan® is used for follow-up of fibrosis and steatosis. This single-cen - ter study aims to review the distribution of indications by referral to Fi - broScan®. Materials and Methods: Demographic characteristics, CLD etiolo - gies, and FibroScan ® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated. Results: Out of 9345 patients, 4946 (52.93%) were males, and the medi- an age was 48 [18–88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepa- titis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with old- er age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597–3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168–3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524–2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360–3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD. Conclusion: NAFLD was the most common indication for referral to FibroScan®.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver dis- ease. Clin Liver Dis (Hoboken) 2021;17(5):365-370. [CrossRef]
2. Ozekinci T, Atmaca S, Dal T. Effect of routine Hepatitis B vaccination program in Southeast of Turkey: Comparing the results of HBV DNA in terms of age groups for the years 2002 and 2012. Cent Eur J Immunol 2014;39(1):122-123. [CrossRef]
3. Ormeci N, Gulsen MT, Sezgin O, Aghayeva S, Demir M, Koksal I, et. al. Treatment of HCV infection with direct-acting antiviral agents. Real life expe- riences from the Euro-Asian region. Turk J Gastroenterol 2020;31(2):148-155.
4. Idilman R, Aydogan M, Oruncu MB, Kartal A, Elhan AH, Ellik Z, et. al. Natural history of cirrhosis: Changing trends in etiology over the years. Dig Dis 2021;39(4):358-365. [CrossRef]
5. Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, et. al. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-cen- ter experience. Turk J Gastroenterol 2019 Oct; 30(10):892-898. [CrossRef]
6. Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prev- alence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. Hepatology Forum 2021;2(2):37-42. [CrossRef]
7. World Health Organization. Noncommunicable diseases: Risk factors. Available at: http://www.who.int/gho/ncd/risk_factors/overweight_obesity/ obesity_adults/en/ Accessed on Jun 18, 2022.
8. Degertekin B, Tozun N, Demir F, Soylemez G, Parkan S, Gurtay E, et al. The changing prevalence of non-alcoholic fatty liver disease (NAFLD) in Turkey in the Last Decade. Turk J Gastroenterol 2021;32(3):302-312. [CrossRef]
9. Ozkan H. Epidemiology of chronic hepatitis B in Turkey. Euroasian Hepa- togastroenterol 2018;8(1):73-74. [CrossRef]
10. Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20(1):249. [CrossRef]
11. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013;25(11):1330–1334. [CrossRef]
12. Kenger EB, Guveli H, Er gun C, Kaya E, Yilmaz Y. The comparison of rest- ing metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients. Hepatol Forum 2020;1(1):14-19. [CrossRef]
13. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57(3):1182-1191. [CrossRef]
14. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gas- troenterol Rep 2014;16(2):372. [CrossRef]
15. Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T. Controlled attenua- tion parameter for assessment of hepatic steatosis grades: a diagnostic me- ta-analysis. Int J Clin Exp Med 2015;8(10):17654-17663.
16. Mueller S. Noninvasive assessment of patients with alcoholic liver disease. Clin Liver Dis (Hoboken) 2013;2(2):68-71. [CrossRef]
17. Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et. al; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020;52(3):513- 526. [CrossRef]
18. Yilmaz Y, Kaya E, Eren F. Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam’s razor applied to advanced fibrosis screening. Aliment Pharmacol Ther 2020;52(11-12):1759-1760.
19. Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, et. al. Nonalcoholic fatty liver disease burden - Saudi Arabia and Unit- ed Arab Emirates 2017-2030. Saudi J Gastroenterol 2018;24(4):211-219.
20. Kaya E, Demir D, Alahdab YO, Yilmaz Y. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol 2016;28(11):1264-1267. [CrossRef]
21. Kaya E, Yilmaz Y. Insidious danger for young adults: Metabolic (dysfunc- tion)-associated fatty liver disease. Hepatol Forum 2022;3(2):39-40. [CrossRef]
22. Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, et. al. Impact of type 2 dia- betes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract 2020;26(4):444-453. [CrossRef]
23. Zhang X, Wong GL, Wong VW. Application of transient elastography in non- alcoholic fatty liver disease. Clin Mol Hepatol 2020;26(2):128-141.[CrossRef]
24. Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, et. al. Ac- curacy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in pa- tients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol 2020;55(4):428-440. [CrossRef]
25. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et. al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatolo- gy 2012;55(1):199-208. [CrossRef]
26. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et. al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71(5):1006-1019. [CrossRef]
27. Foucher J, Castéra L, Bernard PH, Adhoute X, Laharie D, Bertet J, et. al. Prevalence and factors associated with failure of liver stiffness measure- ment using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 2006;18(4):411-412. [CrossRef]
28. Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diag- nostic accuracy of FibroScan and factors affecting measurements. Diagnos- tics (Basel) 2020;10(11):940. [CrossRef]
29. Avcu A, Kaya E, Yilmaz Y. Feasibility of FibroScan in assessment of he- patic steatosis and fibrosis in obese patients: report from a general internal medicine clinic. Turk J Gastroenterol 2021;32(5):466-472. [CrossRef]
30. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et. al. TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28(2):169-180. [CrossRef]
31. Kaya E, Yilmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol 2019;30(10):865-871. [CrossRef]
32. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et. al. Pop- ulation-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002;(9):1551-1556. [CrossRef]
33. Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ et. al.Spec- trum of liver diseases in patients referred for FibroScan: A single center expe- rience in the Middle East. Ann Med Surg (Lond) 2020;57:166-170. [CrossRef]
34. Choudhuri G, Chaudhari S, Pawar D, Roy DS. Etiological patterns, liver fibrosis stages and prescribing patterns of hepato-protective agents in indian patients with chronic liver disease. J Assoc Physicians India 2018;66:58-63.
35. Singh R, Asati P. Spectrum and clinical profile in patients with nonalcoholic fatty liver disease in Central India. J Assoc Physicians India 2020;68:97.
36. Mukherjee PS, Vishnubhatla S, Amarapurkar DN, Das K, Sood A, Chawla YK, et. al. Etiology and mode of presentation of chronic liver diseases in India: A multi centric study. PLoS One 2017;12:e0187033. [CrossRef]
37. Méndez-Sánchez N, Zamarripa-Dorsey F, Panduro A, Purón-González E, Coronado-Alejandro EU, Cortez-Hernández CA, et. al. Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world re- gions. World J Clin Cases 2018;6(15):922-930. [CrossRef]
38. Cekin AH, Cekin Y, Ozdemir A. The level of knowledge of, attitude toward and emphasis given to HBV and HCV infections among healthcare profes- sionals: data from a tertiary hospital in Turkey. Int J Occup Med Environ Health 2013;26(1):122-131. [CrossRef]
39. Baser O, Kariburyo MF, Baser E,AltinbasA. Cost of cirrhosis among patients diagnosed with hepatitis C virus in Turkey. Value Health 2014;17(7):A672.
40. Acikgoz A, Yoruk S, Kissal A, Yildirimcan KS, Catal E, Kamaci G, et. al. Healthcare students’ vaccination status, knowledge, and protective behav- iors regarding hepatitis B: a cross-sectional study in Turkey. Hum Vaccin Immunother 2021;17(11):4595-4602. [CrossRef]
41. Wong RJ, Singal AK. Trends in liver disease etiology among adults await- ing liver transplantation in the United States, 2014-2019. JAMA Network Open 2020;3(2):e1920294. [CrossRef]
42. Andriulli A, Stroffolini T, Mariano A, Valvano MR. Declining prevalence and increasing awareness of HCV infection in Italy: A population-based sur- vey in five metropolitan areas. Eur J Intern Med 2018;53:79-84. [CrossRef]
43. Fedeli U, Schievano E, Lisiero M, Avossa F, Mastrangelo G, Saugo M. Descriptive epidemiology of chronic liver disease in northeastern Italy: an anal- ysis of multiple causes of death. Popul Health Metr 2013;11(1):20. [CrossRef]
44. Fedeli U, Avossa F, Ferroni E, De Paoli A, Donato F, Corti MC. Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity. Heliyon 2019;5(7):e02114. [CrossRef]
45. Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, et. al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20(1):249. [CrossRef]
46. Chahal HS, Marseille EA, Tice JA. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treat- ment-Naive Population. JAMA Intern Med 2016;176(1):65-73. [CrossRef]

APA	Eris T, Hassan M, Hikal Y, E, Daneshgar F, Teker A, Özel F, Lüleci N, Kaya E, Yilmaz Y (2023). Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. , 7 - 13. 10.14744/hf.2022.2022.0042
Chicago	Eris Tansu,Hassan Moomen,Hikal Yousra, Enas sawah,Daneshgar Fatemeh,Teker Ayse Gulsen,Özel Furkan,Lüleci Nimet Emel,Kaya Eda,Yilmaz Yusuf Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. (2023): 7 - 13. 10.14744/hf.2022.2022.0042
MLA	Eris Tansu,Hassan Moomen,Hikal Yousra, Enas sawah,Daneshgar Fatemeh,Teker Ayse Gulsen,Özel Furkan,Lüleci Nimet Emel,Kaya Eda,Yilmaz Yusuf Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. , 2023, ss.7 - 13. 10.14744/hf.2022.2022.0042
AMA	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. . 2023; 7 - 13. 10.14744/hf.2022.2022.0042
Vancouver	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. . 2023; 7 - 13. 10.14744/hf.2022.2022.0042
IEEE	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y "Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease." , ss.7 - 13, 2023. 10.14744/hf.2022.2022.0042
ISNAD	Eris, Tansu vd. "Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease". (2023), 7-13. https://doi.org/10.14744/hf.2022.2022.0042

APA	Eris T, Hassan M, Hikal Y, E, Daneshgar F, Teker A, Özel F, Lüleci N, Kaya E, Yilmaz Y (2023). Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. Hepatology forum, 4(1), 7 - 13. 10.14744/hf.2022.2022.0042
Chicago	Eris Tansu,Hassan Moomen,Hikal Yousra, Enas sawah,Daneshgar Fatemeh,Teker Ayse Gulsen,Özel Furkan,Lüleci Nimet Emel,Kaya Eda,Yilmaz Yusuf Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. Hepatology forum 4, no.1 (2023): 7 - 13. 10.14744/hf.2022.2022.0042
MLA	Eris Tansu,Hassan Moomen,Hikal Yousra, Enas sawah,Daneshgar Fatemeh,Teker Ayse Gulsen,Özel Furkan,Lüleci Nimet Emel,Kaya Eda,Yilmaz Yusuf Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. Hepatology forum, vol.4, no.1, 2023, ss.7 - 13. 10.14744/hf.2022.2022.0042
AMA	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. Hepatology forum. 2023; 4(1): 7 - 13. 10.14744/hf.2022.2022.0042
Vancouver	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease. Hepatology forum. 2023; 4(1): 7 - 13. 10.14744/hf.2022.2022.0042
IEEE	Eris T,Hassan M,Hikal Y, E,Daneshgar F,Teker A,Özel F,Lüleci N,Kaya E,Yilmaz Y "Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease." Hepatology forum, 4, ss.7 - 13, 2023. 10.14744/hf.2022.2022.0042
ISNAD	Eris, Tansu vd. "Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease". Hepatology forum 4/1 (2023), 7-13. https://doi.org/10.14744/hf.2022.2022.0042